Prophylactic effect of riboflavin on pediatric migraine: a randomized, double-blind, placebo-controlled trial

Ahmad, Tariq; Soltani, Behzad; Banafshe, Hamid Reza; Moosavi, Gholam Abbas; Talebian, M.; Soltani, Siamak

doi:10.19082/6279

Cited by 18 publications

(11 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two previous systematic reviews that evaluated the role of riboflavin in the prevention of migraine assessed the same studies (three RCTs and one retrospective study) [ 20 , 21 ]. Among these studies, two—one RCT and one retrospective study—reported that riboflavin was effective [ 22 , 23 ], while the other two reported ineffectiveness [ 24 , 25 ]. The latter two studies concluded that there was a lack of evidence to support the use of riboflavin for pediatric migraine.…”

Section: Resultsmentioning

confidence: 99%

“…The latter two studies concluded that there was a lack of evidence to support the use of riboflavin for pediatric migraine. However, the former two positive studies have recently been published [ 23 , 26 ].…”

Section: Resultsmentioning

confidence: 99%

“…Among the patients who were prescribed 100 mg/day of riboflavin ( n = 30), 400 mg/day of riboflavin ( n = 30), or a placebo ( n = 30), only the participants who were prescribed 400 mg of riboflavin exhibited a significantly decreased headache frequency (9.3 to 2.9 episodes/month) and duration (7.9 to 3.9 h/month) at 12 weeks compared to baseline. There were no significant differences between the low-dose and placebo groups in terms of frequency ( p = 0.49) or mean duration ( p = 0.69) of the migraine attacks [ 23 ].…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Complementary and Integrative Medicines as Prophylactic Agents for Pediatric Migraine: A Narrative Literature Review

Yamanaka

Kanou

Takamatsu

et al. 2021

JCM

View full text Add to dashboard Cite

Complementary and integrative medicines (CIMs) are increasingly used as a preventive antimigraine therapy. In this review, we aimed to summarize the evidence for the efficacy and safety of eight CIMs (riboflavin, coenzyme Q10, magnesium, melatonin, polyunsaturated fatty acids, and combination therapy of feverfew, vitamin D, and ginkgolide B) in pediatric migraine prevention. The level of evidence for riboflavin was relatively high; it was investigated by many studies with five/seven studies demonstrating its efficacy. Five studies investigated the use of melatonin, with one reporting negative results. There was insufficient evidence on the effectiveness of coenzyme Q10, magnesium, and polyunsaturated fatty acids. Combination therapy showed positive potential; however, reports on the individual antimigraine effects of the CIMs were lacking. A definitive conclusion was not reached regarding the specific integrative drugs clinicians should choose for pediatric migraines, owing to low-quality evidence and a limited number of studies. Integrative medications are becoming more common for pediatric migraine prevention as they do not produce serious side effects, and underlying research data suggest their efficacy in preventing migraine. Additional studies are warranted to confirm the role of CIMs in treating patients with migraines.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Complementary and Integrative Medicines as Prophylactic Agents for Pediatric Migraine: A Narrative Literature Review

Yamanaka

Kanou

Takamatsu

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“… 27 28 On this review, we limited the participants to adult population because there was limited number of studies done in paediatric population and a few of the studies done involved other supplements such as riboflavin in paediatric population. 29 All the included studies had small number of participants and this limit the applicability of CoQ10 thus the larger samples size is needed for a better result. The information on adverse events came from only one trial which are diarrhoea and chromaturia.…”

Section: Discussionmentioning

confidence: 99%

Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine—a meta-analysis

et al. 2021

View full text Add to dashboard Cite

ObjectiveTo determine the effects of coenzyme Q10 (CoQ10) for reduction in the severity, frequency of migraine attacks and duration of headache in adult patients with migraine.DesignSystematic review and meta-analysis.Data sourcesCochrane Central Register of Controlled Trials, CENTRAL, MEDLINE, EMBASE, Cumulative Index to Nursing and Allied Health Literature (CINAHL) and Psychological Information Database (PsycINFO) from inception till December 2019.Study selectionAll randomised control trials comparing CoQ10 with placebo or used as an adjunct treatment included in this meta-analysis. Cross-over designs and controlled clinical trials were excluded.Data synthesisHeterogeneity at face value by comparing populations, settings, interventions and outcomes were measured and statistical heterogeneity was assessed by means of the I2 statistic. The treatment effect for dichotomous outcomes were using risk ratios and risk difference, and for continuous outcomes, mean differences (MDs) or standardised mean difference; both with 95% CIs were used. Subgroup analyses were carried out for dosage of CoQ10 and if CoQ10 combined with another supplementation. Sensitivity analysis was used to investigate the impact risk of bias for sequence generation and allocation concealment of included studies.ResultsSix studies with a total of 371 participants were included in the meta-analysis. There is no statistically significant reduction in severity of migraine headache with CoQ10 supplementation. CoQ10 supplementation reduced the duration of headache attacks compared with the control group (MD: −0.19; 95% CI: −0.27 to −0.11; random effects; I2 statistic=0%; p<0.00001). CoQ10 usage reduced the frequency of migraine headache compared with the control group (MD: −1.52; 95% CI: −2.40 to −0.65; random effects; I2 statistic=0%; p<0.001).ConclusionCoQ10 appears to have beneficial effects in reducing duration and frequency of migraine attack.PROSPERO registration numberCRD42019126127.

show abstract

“…Seven previous studies, including four RCTs, evaluated riboflavin’s role in preventing pediatric migraines ( Table 1 ). All studies except for two RCTs reported that riboflavin was effective [ 89 , 90 , 91 , 92 ]; the other two studies lacked evidence to support the use of riboflavin for pediatric migraines [ 93 , 94 ]. The following factors reportedly inhibit the effects of riboflavin: the presence of comorbid headaches, male sex, and age under 12 years [ 91 , 95 ].…”

Section: Clinical Evidence Of Riboflavin Efficacymentioning

confidence: 99%

Experimental and Clinical Evidence of the Effectiveness of Riboflavin on Migraines

et al. 2021

View full text Add to dashboard Cite

Riboflavin, a water-soluble member of the B-vitamin family, plays a vital role in producing energy in mitochondria and reducing inflammation and oxidative stress. Migraine pathogenesis includes neuroinflammation, oxidative stress, and mitochondrial dysfunction. Therefore, riboflavin is increasingly being recognized for its preventive effects on migraines. However, there is no concrete evidence supporting its use because the link between riboflavin and migraines and the underlying mechanisms remains obscure. This review explored the current experimental and clinical evidence of conditions involved in migraine pathogenesis and discussed the role of riboflavin in inhibiting these conditions. Experimental research has demonstrated elevated levels of various oxidative stress markers and pro-inflammatory cytokines in migraines, and riboflavin’s role in reducing these marker levels. Furthermore, clinical research in migraineurs showed increased marker levels and observed riboflavin’s effectiveness in reducing migraines. These findings suggest that inflammation and oxidative stress are associated with migraine pathogenesis, and riboflavin may have neuroprotective effects through its clinically useful anti-inflammatory and anti-oxidative stress properties. Riboflavin’s safety and efficacy suggests its usefulness in migraine prophylaxis; however, insufficient evidence necessitates further study.

show abstract

Prophylactic effect of riboflavin on pediatric migraine: a randomized, double-blind, placebo-controlled trial

Cited by 18 publications

References 24 publications

Complementary and Integrative Medicines as Prophylactic Agents for Pediatric Migraine: A Narrative Literature Review

Complementary and Integrative Medicines as Prophylactic Agents for Pediatric Migraine: A Narrative Literature Review

Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine—a meta-analysis

Experimental and Clinical Evidence of the Effectiveness of Riboflavin on Migraines

Contact Info

Product

Resources

About